HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume – Should You Buy?

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw unusually-strong trading volume on Monday . 36,049 shares were traded during trading, a decline of 27% from the previous session’s volume of 49,466 shares.The stock last traded at $13.6330 and had previously closed at $12.82.

Analyst Ratings Changes

Several analysts recently commented on the company. HSBC upgraded HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Daiwa Securities Group raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Thursday, September 3rd. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Bank of America decreased their price objective on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, HUTCHMED currently has a consensus rating of “Hold” and a consensus target price of $14.87.

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50. The business has a 50 day moving average price of $12.01 and a 200-day moving average price of $12.66.

HUTCHMED (NASDAQ:HCM) last released its earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.09). The company had revenue of $139.14 million during the quarter, compared to analyst estimates of $304.16 million. On average, equities research analysts forecast that HUTCHMED will post 0.23 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Large investors have recently modified their holdings of the stock. State Street Corp increased its stake in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares in the last quarter. M&G PLC boosted its position in shares of HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after purchasing an additional 54,601 shares in the last quarter. Amundi grew its stake in shares of HUTCHMED by 4.0% in the 1st quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after buying an additional 8,916 shares during the period. Jane Street Group LLC grew its stake in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after buying an additional 124,771 shares during the period. Finally, UBS Group AG increased its position in HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after buying an additional 72,614 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines drug research and development capabilities with commercial operations in China and international markets.

HUTCHMED’s oncology portfolio includes fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla for certain patients with metastatic colorectal cancer. The company also develops other targeted therapies, including savolitinib, a MET tyrosine kinase inhibitor, and surufatinib, an angiogenesis and immunomodulatory therapy.